Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin labeling warnings for combined cardiovascular, analgesic use unnecessary -- Bayer.

This article was originally published in The Tan Sheet

Executive Summary

ASPIRIN LABEL ADDITIONAL WARNINGS FOR CARDIOVASCULAR USERS "UNNECESSARY," Bayer asserts in a May 19 letter to FDA. Bayer's comments respond to a recent letter to FDA from McNeil, maker of acetaminophen-containing Tylenol. McNeil had argued that aspirin consumer labeling should advise users to consult a physician about selecting an "appropriate" analgesic/antipyretic for use while taking aspirin for cardiovascular benefits, and should warn of the signs and symptoms of adverse events that might occur while taking aspirin, such as nausea, pain, vomiting or bleeding ("The Tan Sheet" April 28, p. 13).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087118

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel